MedTrace Logo

Dutasteride in Treating Patients With Prostate Cancer

NCT01193855 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-08-26

No results posted yet for this study

Summary

RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This randomized phase II trial is studying how well giving dutasteride works in treating patients with prostate cancer.

Conditions

Interventions

DRUG

dutasteride

DRUG

gadolinium-chelate

OTHER

active surveillance

PROCEDURE

diffusion-weighted magnetic resonance imaging

PROCEDURE

functional magnetic resonance imaging

PROCEDURE

prostate biopsy

PROCEDURE

ultrasound imaging

Sponsors & Collaborators

  • University College London Hospitals

    lead OTHER

Principal Investigators

  • Mark Emberton, MD, FRCS, MBBS · University College London Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01193855 on ClinicalTrials.gov